Neurologic manifestations of systemic immunopathological diseases

Current Treatment Options in Neurology

Volumn 14, Issue 3, 2012, Pages 276-292

  Gotkine, Marc ^a   Vaknin Dembinsky, Adi ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Mononeuritis multiplex; Neuroimmunology; Neurological; Rheumatoid arthritis; Sj grens Syndrome; Systemic lupus erythematosus; Vasculitis

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WARFARIN;

ACNE; AMYOTROPHIC LATERAL SCLEROSIS; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; ANXIETY; ASEPTIC MENINGITIS; ASTHENIA; ATAXIA; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN VASCULITIS; CATARACT; CHILL; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COGNITIVE DEFECT; CRANIAL NEUROPATHY; CUSHINGOID SYNDROME; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG COST; DYSPEPSIA; FEVER; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; INFERTILITY; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRACRANIAL PRESSURE; INTRAOCULAR PRESSURE; KINESIOTHERAPY; LEG CRAMP; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MENINGITIS; MENINGOENCEPHALITIS; MONONEUROPATHY MULTIPLEX; MOOD CHANGE; MOTOR DYSFUNCTION; MYALGIA; MYASTHENIA GRAVIS; MYELITIS; MYOKYMIA; MYOPATHY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROSURGERY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OTOTOXICITY; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PLASMAPHERESIS; POLYARTERITIS NODOSA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SKIN DISEASE; SPEECH THERAPY; SPINAL CORD COMPRESSION; SPINAL CORD DISEASE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VIRUS HEPATITIS; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS; WEIGHT GAIN;

EID: 84865678543     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0171-z     Document Type: Review

References (43)

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
2. Hochberg MC, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35(5):498-502.
3. Rahman A, Isenberg DA. Systemic Lupus Erythematosus. New England Journal of Medicine. 2008;358 (9):929-39. (Pubitemid 351397092)
4. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999;42(10211873): 599-608.
5. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: A study of 41 patients. Neurology. 2007;69 (17698785):644-54. (Pubitemid 47256006)
6. McLaurin EY, et al. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64(15668428):297- 303.
7. Gotkine, M., Y. Fellig, O. Abramsky, Occurrence of CNS demyelinating disease in patients with myasthenia gravis (subsequent correspondence in Neurology 2007;68(16):1326-7).
8. Neurology, 2006. 67 (16966558): P. 881-883.
9. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: Theevidence and the myth. Brain. 2004;127 (15047589):1200-9. (Pubitemid 38623053)
10. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(16420554):295-306.
11. Wilson WA, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum. 1999;42 (7):1309-11. (Pubitemid 30265586)
12. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(11567728): 903-11. (Pubitemid 32900579)
13. Hanly JG, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32 (16078320):1459-6. (Pubitemid 41113965)
14. Agarwal V, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27 (18084807):841-4.
15. Kur-Zalewska J, Swarowska-Knap J, Tlustochowicz W. Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. Pol Arch Med Wewn. 2008;118(18575424):234-7. (Pubitemid 351613065)
16. Bruggemann N, et al. Cranial pachymeningitis: A rare neurological syndrome with heterogeneous aetiology. J Neurol Neurosurg Psychiatry. 2010;81 (20185466):294-8.
17. Delalande S, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine (Baltimore). 2004;83(5):280-91. (Pubitemid 39258414)
18. Masi AT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg- Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-100. (Pubitemid 20273293)
19. Hattori N, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain. 1999;122(Pt 3):427-39. (Pubitemid 29110518)
20. Wolf J, et al. Neurologic complications of Churg- Strauss syndrome-a prospective monocentric study. Eur J Neurol. 2010;17(4):582-8.
21. Reid AJ, et al. Churg-Strauss syndrome in a district hospital. QJM. 1998;91(3):219-29. (Pubitemid 28115855)
22. Guillevin L, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26-37. (Pubitemid 29065978)
23. Solans R, et al. Churg-Strauss syndrome: Outcome and long-term follow-up of 32 patients. Rheumatology (Oxford). 2001;40(7):763-71.
24. Della Rossa A, et al. Churg-Strauss syndrome: Clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford). 2002;41 (11):1286-94. (Pubitemid 35363804)
25. Sehgal M, et al. Neurologic manifestations of Churg- Strauss syndrome. Mayo Clin Proc. 1995;70(4):337- 41.
26. Mencacci NE, et al. Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: Case report and review of the literature. J Neurol Sci. 2011;301(1-2):107-11.
27. Jennette JC, Falk RJ. Small-Vessel Vasculitis. New England Journal of Medicine. 1997;337(21):1512- 23. (Pubitemid 27495778)
28. Nishino H, et al. Neurological involvement in Wegener's granulomatosis: An analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33(1):4-9. (Pubitemid 23009903)
29. Nadeau SE. Neurologic manifestations of systemic vasculitis. Neurol Clin. 2002;20(1):123-50. (Pubitemid 34111656)
30. Gorson KC. Vasculitic neuropathies: An update. Neurologist. 2007;13(1):12-9. (Pubitemid 46095580)
31. Berlit P. Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord. 2010;3(1):29- 42.
32. Sacco RL, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(16432246):577- 617. (Pubitemid 43732031)
33. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-7.
34. De Groot K, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461-9. (Pubitemid 41117433)
35. Keogh KA, et al. Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. AmJ Respir Crit Care Med. 2006;173(2):180-7. (Pubitemid 43187890)
36. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32.
37. Mukhtyar C, et al. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-93-8.
38. Wilde B, et al. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011;79(6):599-612.
39. Magana SM, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68(7):870-8.
40. Faurschou M, et al. Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophos- phamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-5.
41. Black AJ, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129(9):716-8. (Pubitemid 28507145)
42. Brihaye B, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: A study on 8 patients. Clin Exp Rheumatol. 2007;25(17428359):23-7.
43. Seror R, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis. 2007;66 (16950808):351-7. (Pubitemid 46579637)